- Home
- PIII vs NXL Comparison
PIII vs NXL Comparison
Compare PIII & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- NXL
- Stock Information
- Founded
- PIII 2015
- NXL 2010
- Country
- PIII United States
- NXL United States
- Employees
- PIII N/A
- NXL N/A
- Industry
- PIII Medical/Nursing Services
- NXL Medical Specialities
- Sector
- PIII Health Care
- NXL Health Care
- Exchange
- PIII Nasdaq
- NXL Nasdaq
- Market Cap
- PIII 27.8M
- NXL 27.6M
- IPO Year
- PIII N/A
- NXL 2022
- Fundamental
- Price
- PIII $9.22
- NXL $1.52
- Analyst Decision
- PIII Strong Buy
- NXL Strong Buy
- Analyst Count
- PIII 3
- NXL 1
- Target Price
- PIII $17.50
- NXL $5.00
- AVG Volume (30 Days)
- PIII 5.1K
- NXL 10.5M
- Earning Date
- PIII 11-11-2025
- NXL 11-07-2025
- Dividend Yield
- PIII N/A
- NXL N/A
- EPS Growth
- PIII N/A
- NXL N/A
- EPS
- PIII N/A
- NXL N/A
- Revenue
- PIII $1,461,823,000.00
- NXL $174,813.00
- Revenue This Year
- PIII N/A
- NXL $38.28
- Revenue Next Year
- PIII $10.45
- NXL $185.71
- P/E Ratio
- PIII N/A
- NXL N/A
- Revenue Growth
- PIII 4.20
- NXL 16.42
- 52 Week Low
- PIII $5.80
- NXL $0.70
- 52 Week High
- PIII $24.73
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- PIII 54.75
- NXL 59.61
- Support Level
- PIII $8.65
- NXL $1.20
- Resistance Level
- PIII $9.29
- NXL $1.46
- Average True Range (ATR)
- PIII 0.40
- NXL 0.19
- MACD
- PIII -0.03
- NXL 0.04
- Stochastic Oscillator
- PIII 76.24
- NXL 57.53
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.